Shortage of Rocuronium Bromide Injection: FDA Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Rocuronium Bromide Injection, used in anesthesia, with some manufacturers affected as of the latest update on April 1, 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Rocuronium Bromide Injection.
What's in Shortage
The generic drug Rocuronium Bromide Injection, also known by brand names ROCURONIUM BROMIDE and ROCURONIUM, is currently in shortage. It is an injection in the anesthesia therapeutic category. The shortage was first posted on February 15, 2023, and last updated on April 1, 2026.
Which Manufacturers Are Affected
- Baxter Healthcare: Available for presentations including Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10) and 100 mg/10 mL (NDC 43066-013-10). Contact: 888-229-0001.
- Fresenius Kabi USA, LLC: Available for several presentations, such as Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10, NDC 65219-444-10, NDC 65219-442-05, and NDC 63323-426-05), but unavailable for Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05). Related info: Check wholesalers for inventory. Contact: 888-386-1300.
- Hospira, Inc., a Pfizer Company: Available for presentations including Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 0409-3189-10 and NDC 0409-1403-10) and 100 mg/10 mL (NDC 0409-5160-10 and NDC 0409-7037-10). Contact: 844-646-4398.
- Mylan Institutional, a Viatris Company: Available for Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05), but unavailable for Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10) with re-supply expected in April 2026. Contact: 800-796-9526.
Why There's a Shortage
No specific reason was given for this shortage.
What Patients Should Do
Patients who depend on this medication should talk to their pharmacist or healthcare provider to check availability and discuss options. They can also contact the relevant manufacturer for more details. Please remember that patients should always consult their healthcare provider and not make any changes without professional guidance.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,872 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.